SOLVD trial

SOLVD trial
Name	Studies of Left Ventricular Dysfunction (SOLVD)
Phase	Phase III
Status	Completed
Condition	Heart failure, asymptomatic left ventricular dysfunction
Interventions	Enalapril (ACE inhibitor)
Enrollment	~2569
Sponsor	National Heart, Lung, and Blood Institute
Principal investigator	Studies Coordinators Group
Start date	1986
Completion date	1991
Clinicaltrials	NCT (historical)

SOLVD trial The Studies of Left Ventricular Dysfunction (SOLVD) was a pivotal randomized, double‑blind, placebo‑controlled clinical trial evaluating the angiotensin‑converting enzyme inhibitor enalapril in patients with reduced ejection fraction. The trial enrolled patients with symptomatic and asymptomatic left ventricular dysfunction and assessed morbidity and mortality outcomes, influencing guideline recommendations and pharmacotherapy for heart failure across cardiology practice.

Background

The SOLVD program emerged amid growing interest in neurohormonal modulation for heart failure, following observational and experimental work implicating the renin‑angiotensin‑aldosterone system. Influential prior studies and organizations such as the Framingham Heart Study, National Heart, Lung, and Blood Institute, American Heart Association, and investigators associated with the Veterans Affairs Cooperative Studies Program framed the rationale for testing angiotensin‑converting enzyme inhibition. Enalapril, developed by pharmaceutical research groups including Merck & Co., had shown hemodynamic and neurohormonal effects in smaller trials and case series linked to investigators from Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital. Landmark trials in related domains—such as work leading to the CONSENSUS trial and later comparative trials like V-HeFT I and V-HeFT II—provided context for SOLVD's focus on mortality and hospitalization endpoints. The study was designed and overseen by multicenter networks including academic centers at Massachusetts General Hospital, Columbia University Medical Center, and international collaborators.

Methods

SOLVD comprised two parallel randomized arms: the Treatment Trial for patients with symptomatic heart failure and reduced ejection fraction, and the Prevention Trial for patients with asymptomatic left ventricular dysfunction. Enrollment criteria were based on echocardiographic or radionuclide measurement of left ventricular ejection fraction, drawing participants from outpatient clinics affiliated with centers such as Brigham and Women's Hospital, Stanford Health Care, and University of Pennsylvania Health System. The protocol randomized participants to oral enalapril versus matching placebo, using blinding procedures typical of trials coordinated by the National Heart, Lung, and Blood Institute and Data and Safety Monitoring Boards modeled after those in trials like SOLVD's contemporaries. Primary endpoints included all‑cause mortality and a composite of death and heart failure hospitalization, analyzed with intention‑to‑treat and Kaplan‑Meier survival methods; secondary endpoints encompassed exercise tolerance and symptom scores collected at scheduled visits at institutions such as Duke University Hospital and Toronto General Hospital. Statistical oversight and methodology paralleled standards from trials like ISIS-2 and PLATO in randomization and event adjudication, with central laboratories and core echo labs to ensure measurement consistency.

Results

The Treatment Trial demonstrated a statistically significant reduction in all‑cause mortality and a larger effect on hospitalizations for heart failure among symptomatic patients randomized to enalapril relative to placebo, with event curves separating early and sustained over follow‑up. Key contributors to endpoint assessment included committees with representatives from Harvard Medical School, Yale School of Medicine, and University of California, San Francisco. The Prevention Trial in asymptomatic patients showed reductions in the development of clinical heart failure and heart failure hospitalizations, though mortality benefit was less pronounced, echoing patterns observed in subsequent trials like SOLVD's successors and informing aggregate meta‑analyses that incorporated data from trials conducted at centers such as Karolinska Institutet and Imperial College London. Subgroup analyses examined interactions by age, etiology (ischemic versus nonischemic), and baseline ejection fraction, with findings relevant to populations managed in systems like the National Health Service and private clinics in the United States.

Safety and Adverse Events

Adverse event monitoring captured symptomatic hypotension, renal function changes, and hyperkalemia, reported from participating sites including Mount Sinai Hospital and University of Chicago Medical Center. Cough, a class‑specific issue with ACE inhibitors, and rare instances of angioedema were documented and managed per protocol. Safety data were reviewed by a Data and Safety Monitoring Board with experts from institutions such as Columbia-Presbyterian Medical Center and Northwestern Memorial Hospital, and influenced dose‑titration guidance in practice guidelines from bodies like the European Society of Cardiology and American College of Cardiology.

Interpretation and Clinical Impact

SOLVD provided high‑quality evidence that ACE inhibition with enalapril reduced morbidity and mortality in patients with reduced left ventricular ejection fraction, shifting therapeutic paradigms in heart failure care among patients treated in cardiology centers including Cleveland Clinic Foundation and community hospitals affiliated with networks like Kaiser Permanente. The trial informed guideline recommendations from the American Heart Association and European Society of Cardiology and influenced drug labeling and outpatient management algorithms used at institutions such as Beth Israel Deaconess Medical Center and Johns Hopkins Hospital. SOLVD's demonstration of neurohormonal modulation benefits preceded and complemented later evidence for beta‑blockers and mineralocorticoid receptor antagonists evaluated at centers such as University of Glasgow and Università Cattolica del Sacro Cuore.

Subsequent Research and Legacy

SOLVD catalyzed numerous subsequent randomized trials and meta‑analyses, linking to landmark studies including CONSENSUS II, PARADIGM-HF, and trials of angiotensin receptor blockers like CHARM and VALIANT. Long‑term follow‑up studies and registries from networks such as the Get With The Guidelines program and international cohorts at Karolinska Institutet examined real‑world translation of SOLVD findings. Its methodology influenced trial design at multicenter consortia including the Clinical Trials Network and served as a reference point in major reviews published by editorial boards of journals like The New England Journal of Medicine and The Lancet. SOLVD remains a foundational trial in modern cardiology curricula at institutions such as Yale School of Medicine and Harvard Medical School and a touchstone in evidence‑based management of systolic dysfunction.

Category:Clinical trials